Lekarze w zakresie Badanie onkologiczne za granicą — Strona 4

Lekarz jest onkologiem specjalizującym się w leczeniu raka piersi, płuc i przewodu pokarmowego. Obecnie lekarz praktykuje w Szpitalu Uniwersyteckim Istinye Liv.

Z karierą obejmującą wiele renomowanych instytucji, lekarz pracował jako specjalista chorób wewnętrznych w Szpitalu Państwowym w Malatyi, lekarz w Klinice Onkologicznej w Ankarze oraz członek Oddziału Onkologii w Regionalnym Szpitalu Szkoleniowo-Badawczym w Erzurum.

Lekarz ukończył Wydział Medyczny Uniwersytetu Selcuk i uzyskał tytuł profesora nadzwyczajnego w 2016 roku.

Dr. Viktor Alexander Krol is the Chief Physician of Gastroenterology and Internal Medicine at St. Martinus-Krankenhaus Düsseldorf. He also directs a certified Obesity Treatment Center. Dr. Krol treats complex diseases of the digestive tract, metabolism, and respiratory system. He works at one of only two German clinics accredited by the International Federation of Obesity.

• Performs bariatric surgeries and endoscopic weight loss procedures.
• Treats gastrointestinal conditions like pancreatitis, Crohn's disease, and cirrhosis.
• Manages internal medicine cases across cardiology, diabetology, and nephrology.
• Uses diagnostic tools including gastroscopy with biopsy and endosonography.

Dr. Cemil Bilir is a professor of medical oncology at VM Medical Park Pendik Hospital in Istanbul. He specializes in immunotherapy and chemotherapy for lung, breast, and prostate cancers. A former research fellow at Northeastern University in Boston, he focused on pharmaceutical biotechnology and nanomedicine. Dr. Bilir works at a JCI-accredited facility where academic physicians provide around-the-clock care.

• Member of the American Society of Clinical Oncology (ASCO) and ESMO.
• Completed a specialized clinical rotation at the Cleveland Clinic in the U.S.
• Treats complex oncological cases, including stage 4 lung cancer and sarcoma.
• Current Ph.D. student in inorganic chemistry at Sakarya University.

Dr. Qasim Wasim holds an MBBS and master’s and PhD degrees in general surgery from Dalian Medical University. He is a PMDC board-certified general practitioner with over 10 years of experience. He served as a resident at Shaikh Zayed Medical Complex and at Nawaz Sharif Social Security Hospital in Lahore.

He manages cases in internal medicine, general surgery, obstetrics and gynecology, pediatrics, and dermatology. He also handles emergencies such as trauma, fractures, cardiac events, and burns. He is multilingual and serves an international community. He has authored over eight SCI-indexed research papers on intestinal ischemia–reperfusion injury and surgical biomechanics.

Dr. Zuhal Cakmak Peksen is a Family Medicine Specialist since 2017. She earned her MD from Çukurova University in 2010. She completed specialty training at Yüzüncü Yıl University between 2013 and 2017. She is currently studying for a bachelor’s degree in Health Management at Anadolu University (2024–present).

She has 15 years of clinical practice (2010–2025) across 8 institutions. Her experience includes research in Family Medicine (2013–2017) and work at several Family Health Centers. Since 2020, she has served at TOKİ Avrupa Family Health Center in Gaziosmanpaşa, Istanbul.

Assoc. Prof. Ayşe İrem Yasin, M.D., is a medical oncologist who specializes in solid tumors. Her clinical focus includes breast, lung, gastrointestinal, gynecologic, and urologic cancers. She also treats brain and other CNS tumors, soft tissue sarcomas, head and neck cancers, adenocarcinomas, melanoma, Merkel cell carcinoma, and cancers of unknown primary. She practices at Medipol Acıbadem District Hospital (2025–present). She previously worked at Şişli Etfal Training and Research Hospital (2023–2025).

She completed a Medical Oncology fellowship at Bezmialem Vakıf University (2019–2022). This followed an Internal Medicine residency at the same institution (2012–2016). Her international experience includes the Breast Cancer Unit at the University of Piemonte Orientale in Novara (2022). She also trained at Basel University Hospital, Cleveland Clinic, and Harvard Medical School. She holds the ESMO Board Certificate (2022).

Dr. Hasan Mutlu is a medical oncologist at Medical Park Antalya Hospital Complex. He specializes in immunotherapy, targeted cancer therapies, and genetic research in cancer treatment. Dr. Mutlu received his medical degree from Hacettepe University. He holds the title of Professor of Medicine. Dr. Mutlu focuses on organ tumor diagnosis and chemotherapy.

• Specializes in both medical and pediatric oncology cases.
• Treats complex conditions including neuroblastoma, Wilms tumor, and Ewing's sarcoma.
• Performs biological therapies and stays active in next-generation genetic research.
• Works at the Mediterranean region’s largest private hospital with PET-CT and LINAC technology.

Dr. Mustafa Serkan Alemdar is a clinical oncologist at Medical Park Antalya Hospital Complex. He specializes in treating complex solid tumors and blood cancers. Dr. Alemdar completed his medical degree and oncology fellowship at Akdeniz University. He is an active member of the Turkish Society of Medical Oncology.

• Treats a wide range of cancers including breast, lung, and prostate.
• Expert in hematology-oncology for conditions like leukemia, myeloma, and lymphoma.
• Performs systemic therapies such as chemotherapy, immunotherapy, and targeted biological therapy.
• Works at a facility that houses specialized oncology-bone marrow units and LINAC technology.

Lekarz jest onkologiem klinicznym i radioterapeutą z 33-letnim doświadczeniem, specjalizującym się w onkologii i radioterapii. Ukończył Uniwersytecki Szpital Hadassah w Jerozolimie, Izrael, i posiada kwalifikacje w obu dziedzinach onkologii i radioterapii.<\/p>

Obecnie pełni funkcję kierownika Centrum Raka Przewodu Pokarmowego, a także jest starszym lekarzem w Oddziale Onkologii w Uniwersyteckim Szpitalu Hadassah. Ukończył egzaminy specjalizacyjne z onkologii i radioterapii i jest członkiem kilku towarzystw zawodowych, w tym Izraelskiego Towarzystwa Onkologii Klinicznej i Izraelskiego Stowarzyszenia Walki z Rakiem.<\/p>

Professor Shixin Liu, MD, PhD, is the Discipline Leader of the Oncology Center. He is the former President of Jilin Provincial Cancer Hospital and former Director of the Cancer Prevention and Treatment Research Institute. He is a second-level professor and doctoral supervisor. He has received the State Council Special Government Allowance, the 4th National Famous Doctor (Outstanding Contribution) award, and the Model of Medical Ethics honor.

He specializes in the comprehensive diagnosis and treatment of malignant tumors. His focus is precision radiotherapy for thoracic and abdominal cancers. He is skilled in IMRT, VMAT, and SBRT for lung, esophageal, breast, and rectal cancers.

His leadership roles include Vice Chair of CMA Radiation Oncology, CACA Radiotherapy, and CACA Particle Therapy. He serves on the CSCO Standing Committee and as Vice Chair of the CSCO Radiation Oncology Expert Committee. He is Vice Chair of CPAM Radiation Oncology and a Standing Committee member of CSMEA. He chairs the Jilin Medical Association Radiation Oncology branch. He is on the editorial boards of the Chinese Journal of Radiation Oncology and the Practical Journal of Cancer.

Dr. Ercan Ozden is a medical oncologist and internal medicine specialist at VM Medical Park Pendik. He provides treatment for a wide range of cancers, including breast, lung, and colon cancer. Dr. Ozden trained at Istanbul University, Cerrahpasa Faculty of Medicine. He later completed a medical oncology subspecialty at Kocaeli University.

• Specializes in immunotherapy, target therapy, and chemotherapy for complex cases.
• Treats patients at a JCI-accredited hospital in Istanbul.
• Performs staging and biopsies for liver, lung, and pancreatic tumors.
• Provides targeted immunotherapy using medications like Keytruda.

Assoc. Prof. Atakan Topçu, M.D., is a medical oncologist at Medipol University and Medipol Acıbadem Regional Hospital. He treats solid tumors, including lung, breast, colorectal, gastric, and neuroendocrine cancers. His work also covers targeted therapies, immunotherapy, geriatric oncology, and cancer-related malnutrition, cachexia, and sarcopenia.

He has authored more than 50 peer-reviewed papers. Recent work includes a 2024 Frontiers in Medicine study on geriatric syndromes and a 2023 Future Oncology paper on sarcopenia and anxiety in lung cancer. He has also published on the CONUT score in breast cancer and on malnutrition in HER2-negative metastatic gastric cancer.

Dr. Topçu serves on the Editorial Board of BMC Cancer. He is a member of the Turkish Society of Medical Oncology, ESMO, and the Turkish Geriatrics Society. Education and training: M.D., Uludağ University; residency in Internal Medicine, Marmara University; fellowship in Medical Oncology, Bezmialem Vakıf University.

Dr. Irfan Cicin is a Professor of Medical Oncology at the Trakya University Faculty of Medicine (2015–present). He has over 20 years of medical oncology experience and has held academic roles since 2010.

Education: MD, Istanbul University – Cerrahpaşa (1991–1997). Residency in Internal Medicine, Trakya University (1997–2002). Fellowship in Medical Oncology, Trakya University (2002–2004).

Practice: Medical Oncologist, Trakya University (2005–2008). Medical Oncologist, Elazığ Training and Research Hospital (2008–2010). Associate Professor of Medical Oncology, Trakya University (2010–2015). He previously served as a physician in the Turkish Air Force at Etimesgut Military Hospital (2004–2005).

Dr. Muhammed Mustafa Atci is an Associate Professor of Medical Oncology at İstinye University, Liv Hospital Topkapı (2025–present). He previously served as Associate Professor and Education Coordinator at Prof. Dr. Cemil Taşcıoğlu City Hospital (2023–2025). He was also a Medical Oncologist there (2018–2021).

He has been a member of ASCO and the Turkish Society of Medical Oncology since 2018. He is the author or co-author of 19 peer-reviewed international papers on colon, breast, gastric, pancreatic, lung, thyroid, sarcoma, and colorectal cancers.

Notable works include a multicentre study on stage IIB colon cancer survival (Journal of Chemotherapy). He also studied the De Ritis ratio for lung metastasis in testicular cancer (Current Urology). His prognostic studies used PET/CT, MSI, lymph node ratio, and metabolic tumor volume.

Lekarz kieruje Centrum Czerniaka i Immunoterapii Raka w Centrum Medycznym Hadassah, koncentrując się na innowacyjnych badaniach i leczeniu pacjentów. Specjalizując się w badaniu rodziny receptorów SLAM, lekarz jest na czele badań nad odpowiedzią immunologiczną przeciwko rakowi.<\/p>

Zaangażowany w leczenie pacjentów z czerniakiem za pomocą nowych terapii immunologicznych, lekarz współpracuje z zespołem klinicystów i badaczy. Ta współpraca zapewnia natychmiastowy dostęp do danych klinicznych i tkanek pochodzących od pacjentów, co zwiększa wysiłki badawcze translacyjne.<\/p>

Dr. Joseba Rebollo Liceaga is a clinical oncologist at Quirónsalud Alicante. He focuses on personalized cancer treatments and gene-based therapies for metastatic breast cancer. Dr. Rebollo Liceaga teaches as a professor of Multidisciplinary and Personalized Oncology. He treats various conditions, including prostate, colon, and thyroid cancers.

• Former Head of Oncology at Clínica San Miguel and Hospital General de Villalba.
• Researches electrochemotherapy and multidisciplinary approaches for complex cases.
• Practices at JCI-accredited Quirónsalud Torrevieja, a leading center in southeastern Spain.
• Expert in diagnostics using PET-CT, mammography, and tumor marker blood tests.

Prof. Ben Boursi is a physician in the Gastrointestinal Cancer Department at Sheba Medical Center. He specializes in internal medicine, medical oncology, and cancer epidemiology. He is board certified in internal medicine and medical oncology. He earned a B.Med.Sc (summa cum laude) and an MD (magna cum laude) from Tel Aviv University.

He completed clinical and research fellowships in GI oncology and cancer epidemiology at the University of Pennsylvania. He also completed electives at MD Anderson and Mayo Clinic. He founded the ECOG-ACRIN Microbiome Working Group. His microbiome-oncology research has been published in leading journals, including Science, and highlighted by ASCO.

He developed predictive models for early diagnosis of colorectal and pancreatic cancers. These models are now in clinical evaluation. He holds an academic appointment at Tel Aviv University. He is also an Associate Scholar at the University of Pennsylvania.

Dr. Yaacov Lawrence, MA, MBBS, MRCP, is Chair of Radiation Oncology at Sheba Medical Center. He has nearly 30 years of experience in precision radiation oncology and neuro-oncology.

He is an expert in advanced radiation therapy and radiosurgery. He performs stereotactic radiosurgery for brain tumors. He leads Sheba’s GI Cancer Program in gastrointestinal oncology. He also provides precision care for lung and prostate cancers. He pioneered celiac plexus radiosurgery for severe pain from pancreatic cancer.

Training and credentials: MA and MBBS (Cambridge and UCLH); MRCP (RCP); Radiation Oncology fellowship (Thomas Jefferson University). Honors include the ASCO Young Investigator Award and Fellow of ASTRO (FASTRO). He has authored over 280 publications. He is Director of the Center for Translational Radiation Oncology and an Associate Professor at Tel Aviv University.

Dr. Eytan Aharon Ben‑Ami, MD, is a Senior Physician in the Sarcoma and Bone Oncology Service at Sheba Medical Center. He heads the Oncology Division and the Early-Phase Clinical Trials Unit. He founded the Sheba Clinical Research Organization. He is an academic affiliate at Tel Aviv University.

He specializes in sarcomas and primary bone tumors, including soft tissue sarcoma, liposarcoma, leiomyosarcoma, and osteosarcoma. He leads Phase I trials in targeted therapy and immunotherapy. He designs personalized treatment plans for rare cancers. He also develops patient-centered programs, including pilots in advanced immunotherapy delivery.

He completed a fellowship in Sarcoma and Bone Oncology at the Dana-Farber Cancer Institute/Harvard Cancer Center. He has authored more than 40 publications on early detection, molecular and viral mechanisms, and new cancer therapies.